FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of structural formula I or a pharmaceutically acceptable salt thereof, which can be used for inhibiting the activity of lysine-specific histone demethylase 1A (KDM1A) and treating diseases associated with this activity. In formula I m is selected from 1, 2, 3 and 4; R1 represents a nitrogen-containing heterocycloalkyl or heteroaryl, each of which is optionally substituted with 1, 2 or 3 R5 groups, where heterocycloalkyl refers to a saturated monocyclic or bicyclic 3-8 membered heterocyclic group containing from 1 to 2 heteroatoms as ring members, wherein each said heteroatom may be independently selected from nitrogen, oxygen and sulfur; and wherein heteroaryl refers to an aromatic monocyclic 5-6 membered heterocyclic ring that contains from 1 to 2 heteroatoms as ring members, each heteroatom being independently selected from nitrogen; R2 represents H or is selected from C1-C6 alkyl, C3-C7 cycloalkyl, C6 aryl and heteroaryl, any of which is optionally substituted with 1, 2 or 3 R6 groups, where heteroaryl refers to an aromatic monocyclic 5- a 6-membered heterocyclic ring which contains from 1 to 2 heteroatoms as ring members, each said heteroatom being independently selected from nitrogen; R3 is selected from C6 aryl, which is optionally substituted with 1, 2 or 3 R7 groups; each R4 represents hydrogen; each R5 is independently selected from C1-C6 alkyl, oxo, CONR8R9, COOR8 and SO2R8 ; each R6 is independently selected from halogen, C6 haloaryl, C1-C6 alkoxy-C6 aryl, C6 aryl, heteroaryl, cyano, C1-C6 alkoxy, SO2R8 and SO2NR8R9, where heteroaryl refers to an aromatic monocyclic 5-6 membered heterocyclic ring that contains from 1 to 3 heteroatoms as ring members, each heteroatom being independently selected from nitrogen; each R7 is independently selected from halogen, and each R8 and R9 is independently selected from hydrogen and C1-C6 alkyl.
EFFECT: invention also relates to a pharmaceutical composition containing the specified compound.
32 cl, 1 tbl, 48 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
| CYCLOPENTANE COMPOUNDS | 2019 |
|
RU2794997C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| NOVEL THIENO-PYRIMIDINE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2014 |
|
RU2605403C2 |
